市场调查报告书
商品编码
1422067
全球全基因组定序市场:按产品类型,技术,生物体,应用,最终用户,地区,机会,预测2017-2031 年Whole Genome Sequencing Market Assessment, By Product Type, By Technology, By Organism, By Application, By End-Users, By Region, Opportunities and Forecast, 2017-2031F |
2023年全球全基因组定序市场规模达34.4亿美元。预计到 2031 年,该市场将达到 141.2 亿美元,2024-2031 年预测期间复合年增长率为 19.31%。市场成长的关键驱动力是医疗保健专业人员准确诊断和预测癌症和糖尿病等慢性和遗传疾病的能力,帮助他们制定有效的治疗计划和疾病管理策略。
全基因组定序提供了一种早期检测导致慢性疾病的基因突变的方法。全基因组定序对产业的需求日益增长,因为它可用于高精度诊断各种慢性疾病,如囊性纤维化和其他遗传异常。由于从事药物开发、农业研究和法医学等各种项目的基因研究人员数量不断增加,全基因组定序产品的需求量很大。由于政府对科学研究、开发和技术突破的资助,预计该行业将显着增长。然而,产品成本高、缺乏熟练的专业人员、复杂的数据解释等成为阻碍全球全基因组定序市场成长的障碍。
遗传异常和慢性疾病发生率的增加是全基因组定序市场的主要驱动力。癌症、心血管疾病和其他疾病等慢性病的发生率和盛行率不断增加,推动了基于全基因组定序的诊断的需求。全基因组定序可以大大帮助许多疾病的诊断和治疗,从而增加了对相关产品和服务的需求。全基因组定序技术由于能够识别特定疾病指标并预测个体对治疗的反应而变得越来越受欢迎。
该报告调查了全球全基因组定序市场,并提供了市场概述,包括按产品类型、技术、有机体、应用、最终用户、地区以及进入市场的公司概况划分的趋势。
Global whole genome sequencing market size was valued at USD 3.44 billion in 2023 and is expected to reach USD 14.12 billion in 2031, with a CAGR of 19.31% for the forecast period between 2024 and 2031F. The ability of healthcare practitioners to precisely diagnose and predict chronic and genetic diseases, such as cancers and diabetes, which can help in the development of efficient treatment plans and disease management strategies, is acting as a major driver for the market growth.
Whole genome sequencing provides an early means of detecting genetic mutations that cause chronic disease. There is an increasing need for this industry since whole genome sequencing can be used to diagnose various chronic diseases and other genetic abnormalities, such as cystic fibrosis with high precision. Whole genome sequencing products are high in demand due to the growing number of genetic researchers working on various projects such as medication development, agricultural research, and forensics. The industry is anticipated to grow significantly as a result of government funding for scientific research and development as well as technological breakthroughs. However, the high cost associated with products, the lack of highly skilled professionals, and the interpretation of complicated data are some of the hindrances that can hamper the growth of the global whole genome sequencing market.
In March 2023, Illumina Inc. announced the launch of its first product based on its novel Illumina Complete Long Read technology. Illumina Inc. is a global provider of products used in DNA sequencing and array-based technologies. Illumina Complete Long Read Prep, Human is a high-performance, long-read, human whole-genome sequencing (WGS) assay that is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. Illumina Complete Long Reads offers long and short-read sequencing in the same instrument for the first time and enable a simpler workflow as compared to other long-read offerings.
The rising incidence of genetic abnormalities and chronic diseases significantly drives the market for whole genome sequencing. The rising incidence and prevalence of chronic illnesses such as cancer, cardiovascular diseases, and other conditions is fueling the need for whole genome sequencing-based diagnosis. The diagnosis and treatment of many disorders are greatly aided by whole genome sequencing, which has increased demand for related products and services. Whole genome sequencing techniques are becoming increasingly popular due to their ability to identify specific disease indicators and predict individual responses to therapies.
According to a factsheet updated by WHO in September 2023, noncommunicable diseases (NCDs) are responsible for killing 41 million people each year, equivalent to 74% of all deaths globally. Around 17 million people die from NCDs before the age of 70 years; 86% of these premature deaths occur in low- and middle-income countries. Cardiovascular diseases (CVDs) account for most NCD deaths, (17.9 million people annually), followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).
The global whole genome sequencing market is positively impacted by increasing research and development surrounding genome exploration and its various benefits applications. Over the past few decades, the human genome projects have significantly contributed to the growing body of research concerning genome explorations. The market is anticipated to rise significantly in collaboration with the growing acceptance and application of NGS and Sanger technology in institutional and academic research projects.
For instance, in November 2023, UK Biobank Limited released the world's largest-by-far single set of sequencing data by investing EUR 200 million and conducted continuous research for five years into the public domain. The development of innovative diagnostics, therapies, and cures is expected to be fueled by this data. Researchers across the globe can access the data through a secure database that exclusively holds de-identified data.
For precise identification of single nucleotide mutations and minor insertions/deletions, Sanger sequencing is regarded as the gold standard. Sanger sequencing is preferred over other sequencing techniques due to its precision and accuracy. The segment is anticipated to lead the whole genome sequencing market's technology for the duration of the forecasted period due to the growing usage of Sanger sequencing. Numerous industry participants are committed to growing their businesses and offering more fast and accurate whole genome sequencing services.
In October 2023, Wellcome Sanger Institute announced the launch of 'Generative and Synthetic Genomics Program' to enhance research efforts on the 'Human Genetics' and 'Tree of Life' programs. By producing vast volumes of genomic data to feed into computer models will anticipate their consequences, such as the influence of mutations on disease, it seeks to bring together computational and experimental scientists to understand and forecast the impacts of editing DNA. Additionally, the researchers are expected to create tools for writing and editing genomes.
North America is anticipated to dominate the market with the highest value share due to of its significant investment in R&D, technical breakthroughs made by major companies, and highly developed healthcare infrastructure in North American nations like the United States and Canada. Initiatives by the government are expected to expedite medication development process and cancer treatment, contributing to the market growth. In May 2023, The National Institutes of Health (NIH) launched a new program called Common Fund's Somatic Mosaicism Across Human Tissues (SMaHT) Network worth USD 140 million to explore knowledge about genetic variation in normal human cells and tissues.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using various strategies. Companies are expanding the range of products they offer to gain market share. Industry participants are using a variety of growth methods, including collaborations, mergers and acquisitions, product launches, and the development of new goods, to bolster their positions in the market.
In July 2023, MedGenome announced the acquisition of Illumina's NovaSeq X Plus. MedGenome is a leading global genomic diagnostic and research services organization in South Asia. The acquisition makes MedGenome the first to offer advanced genomics services using Illumina's NovaSeq X Plus in South Asia. Through the acquisition, the company anticipates cutting down the reagent cost of human whole genome sequencing to USD 200. MedGenome announced the launch of KaryoSeq (or Karyotype Sequencing), which is an innovative whole genome sequencing to diagnose prenatal and newborn conditions.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.